Pfizer and BioNTech have commenced the dosing of participants in a Phase I/II clinical trial assessing the BNT162 vaccine candidate to protect against Covid-19 in the US.
The study is part of a global development programme and the dosing of initial participants in Germany was concluded last week.
Go deeper with GlobalData
During the Phase I/II protocol, the safety, immunogenicity and optimal dose level of four mRNA vaccine candidates will be assessed in a single, continuous study. The trial’s dose level escalation part in the US will involve up to 360 healthy participants.
